logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia

Abongomera C, Ritmeijer KKD, Vogt F, Buyze J, Mekonnen Z,  et al.
2017-06-05 • PLOS One
2017-06-05 • PLOS One
BACKGROUND
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A clinical prognostic score for death in VL patients could contribute to...
Journal Article
|
Research

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study

Abongomera C, Diro EGJ, de Lima Pereira A, Buyze J, Stille K,  et al.
2018-05-25 • PLOS Neglected Tropical Diseases
2018-05-25 • PLOS Neglected Tropical Diseases
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and...
Journal Article
|
Research

A comparison of the effectiveness of sodium stibogluconate monotherapy to sodium stibogluconate and paromomycin combination for the treatment of severe post kala azar dermal leishmaniasis in South Sudan - A retrospective cohort study

Abongomera C, Gatluak F, Buyze J, Ritmeijer KKD
2016-09-22 • PLOS One
2016-09-22 • PLOS One
BACKGROUND
Post-kala-azar dermal leishmaniasis (PKDL) is a common dermatological complication following successful treatment of Visceral Leishmaniasis (VL) caused by Leishmania donov...
Journal Article
|
Research

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

Diro EGJ, Edwards T, Ritmeijer KKD, Fikre H, Abongomera C,  et al.
2019-02-21 • PLOS Neglected Tropical Diseases
2019-02-21 • PLOS Neglected Tropical Diseases
BACKGROUND:
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is ...
Journal Article
|
Research

The risk and predictors of visceral leishmaniasis relapse in HIV co-infected patients in Ethiopia: a retrospective cohort study

Abongomera C, Diro EGJ, Vogt F, Tsoumanis A, Mekonnen Z,  et al.
2017-10-30 • Clinical Infectious Diseases
2017-10-30 • Clinical Infectious Diseases
BACKGROUND
East Africa, where Leishmania donovani is prevalent, faces the highest burden world-wide of visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) coinfection...
Journal Article
|
Research

Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in northwest Ethiopia?

Aderie EM, Diro EGJ, Zachariah R, da Fonseca M, Abongomera C,  et al.
2017-06-13 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2017-06-13 • Transactions of the Royal Society of Tropical Medicine and Hygiene
BACKGROUND
Visceral leishmaniasis (VL) patients with HIV co-infection should receive antiretroviral treatment (ART). However, the best timing for initiation of ART is not known. Amon...
Journal Article
|
Research

Long-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial

Diro EGJ, Ritmeijer KKD, Boelaert M, Alves F, Mohammed R,  et al.
2017-09-13 • Clinical Infectious Diseases
2017-09-13 • Clinical Infectious Diseases
We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 m...
Journal Article
|
Research

Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient

Abongomera C, Battaglioli T, Adera C, Ritmeijer KKD
2019-04-01 • International Journal of Infectious Diseases
2019-04-01 • International Journal of Infectious Diseases
Post-kala-azar dermal leishmaniasis (PKDL) is a neglected tropical disease characterized by a dermatosis which often appears after successful treatment of visceral leishmaniasis caused b...